Retatrutide Availability and Cost: Global Access Timeline

Regulatory Approval Timeline

• Phase 3 Trials: Completion expected Q1 2026

• FDA Submission: Mid-2026

• Projected Approval: Late 2027

Expected Pricing Structure

Based on current GLP-1 analogs:

Manufacturing Capacity

Eli Lilly is scaling production to avoid shortages seen with Zepbound. Initial supply will prioritize:

1. Clinical trial participants

2. Tier 3 obesity patients

3. Private healthcare networks

Patient Access Programs

Anticipated initiatives:

• Income-based discounts: 30-50% reductions

• Copay cards: $25/month for commercially insured

• Trial extensions: Continued access post-approval

Frequently Asked Questions

Q: Will insurance cover retatrutide?
A: Initially unlikely. Most insurers require 6+ months of prior authorization.

Q: How does cost compare to semaglutide?
A: Expected to be 20-30% higher due to triple-action mechanism.

Q: Can I pre-order retatrutide?
A: No legitimate pre-orders exist. Beware of advance payment scams.